Kylo 0603
Alternative Names: Kylo-0603Latest Information Update: 06 May 2024
At a glance
- Originator Kylonova (Xiamen) Biopharma
- Class Hepatoprotectants
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis